New concepts in asthma: clinical phenotypes and pathophysiological mechanisms

Drug Discovery Today

Volumn 22, Issue 2, 2017, Pages 388-396

  Koczulla, Andreas R ^a   Vogelmeier, Claus F ^a   Garn, Holger ^b   Renz, Harald ^b  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CORTICOSTEROID; LEBRIKIZUMAB; LIGELIZUMAB; MACROLIDE; MEPOLIZUMAB; MONOCLONAL ANTIBODY; NITRIC OXIDE; OMALIZUMAB; PITRAKINRA; RESLIZUMAB; SETIPIPRANT; TRANSCRIPTION FACTOR RUNX2;

ALLERGIC ASTHMA; ASTHMA; BLOOD; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; ELECTRONIC NOSE; EOSINOPHIL; EXERCISE INDUCED ASTHMA; HUMAN; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW; SMOKING; TH2 CELL; ANIMAL; IMMUNOLOGY;

ANIMALS; ASTHMA; HUMANS; PHENOTYPE;

EID: 85008174139     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.11.008     Document Type: Review

References (126)

1. 1 Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention. Available at: http://www.ginasthma org/.
2. 2 Chung, K.F., et al. From the authors: International European Respiratory Society/American Thoracic Society guidelines on severe asthma. Eur. Respir. J. 44 (2014), 1378–1379.
3. 3 Wenzel, S.E., Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 18 (2012), 716–725.
4. 4 Masoli, M., et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 (2004), 469–478.
5. 5 Vink, N.M., et al. Gender differences in asthma development and remission during transition through puberty: the TRacking Adolescents’ Individual Lives Survey (TRAILS) study. J. Allergy Clin. Immunol. 126 (2010), 498–504.
6. 6 Bray, G.W., The hereditary factor in asthma and other allergies. Br. Med. J. 1 (1930), 384–387.
7. 7 Lau, S., et al. Early exposure to house-dust mite and cat allergens and development of childhood asthma: a cohort study. Multicentre Allergy Study Group. Lancet 356 (2000), 1392–1397.
8. 8 Bouzigon, E., et al. Effect of 17q21 variants and smoking exposure in early-onset asthma. N. Engl. J. Med. 359 (2008), 1985–1994.
9. 9 de Nijs, S.B., et al. Adult-onset asthma: is it really different?. Eur. Respir. Rev. 22 (2013), 44–52.
10. 10 Hesselmar, B., et al. The heterogeneity of asthma phenotypes in children and young adults. J. Allergy, 2012, 2012, 163089.
11. 11 Wenzel, S., Severe asthma: from characteristics to phenotypes to endotypes. Clin. Exp. Allergy 42 (2012), 650–658.
12. 12 Hayashi, T., et al. Induction and inhibition of the Th2 phenotype spread: implications for childhood asthma. J. Immunol. 174 (2005), 5864–5873.
13. 13 Szefler, S.J., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 115 (2005), 233–242.
14. 14 Martinez, F.D., et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N. Engl. J. Med. 332 (1995), 133–138.
15. 15 Krishnamoorthy, N., et al. Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat. Med. 18 (2012), 1525–1530.
16. 16 Dusser, D., et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 62 (2007), 591–604.
17. 17 Cazzoletti, L., et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. J. Allergy Clin. Immunol. 120 (2007), 1360–1367.
18. 18 Samter, M., et al. Concerning the nature of intolerance to aspirin. J. Allergy 40 (1967), 281–293.
19. 19 Pavord, I.D., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.
20. 20 McDonald, V.M., et al. Exacerbations of severe asthma. Clin. Exp. Allergy 42 (2012), 670–677.
21. 21 Haldar, P., et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 178 (2008), 218–224.
22. 22 Miranda, C., et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J. Allergy Clin. Immunol. 113 (2004), 101–108.
23. 23 Castro, M., et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 184 (2011), 1125–1132.
24. 24 Gevaert, P., et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin. Immunol. 128 (2011), 989–995.
25. 25 Green, R.H., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002), 1715–1721.
26. 26 Jayaram, L., et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur. Respir. J. 27 (2006), 483–494.
27. 27 Belda, J., et al. Induced sputum cell counts in healthy adults. Am. J. Respir. Crit. Care Med. 161 (2000), 475–478.
28. 28 Spanevello, A., et al. Induced sputum cellularity. Reference values and distribution in normal volunteers. Am. J. Respir. Crit. Care Med. 162 (2000), 1172–1174.
29. 29 Wenzel, S.E., et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 160 (1999), 1001–1008.
30. 30 Woodruff, P.G., et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 180 (2009), 388–395.
31. 31 Gibson, P.G., et al. Asthma in older adults. Lancet 376 (2010), 803–813.
32. 32 Radenne, F., et al. Asthma in the elderly. Rev. Mal. Respir., 21, 2004 8S117–8S125.
33. 33 Radenne, F., et al. Asthma in the elderly. Rev. Mal. Respir. 20 (2003), 95–103.
34. 34 Kitch, B.T., et al. Late onset asthma: epidemiology, diagnosis and treatment. Drugs Aging 17 (2000), 385–397.
35. 35 Melani, A.S., Management of asthma in the elderly patient. Clin. Interv. Aging 8 (2013), 913–922.
36. 36 Moffatt, M.F., et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363 (2010), 1211–1221.
37. 37 Shaheen, S.O., Changing patterns of childhood infection and the rise in allergic disease. Clin. Exp. Allergy 25 (1995), 1034–1037.
38. 38 Jackson, D.J., et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am. J. Respir. Crit. Care Med. 178 (2008), 667–672.
39. 39 Weinberger, M., Consensus statement from a conference on treatment of viral respiratory infection-induced asthma in young children. J. Pediatr. 142 (2003), S45–S46.
40. 40 Weinberger, M., Treatment strategies for viral respiratory infection-induced asthma. J. Pediatr. 142 (2003), S34–S38.
41. 41 Folkerts, G., et al. Virus-induced airway hyperresponsiveness and asthma. Am. J. Respir. Crit. Care Med. 157 (1998), 1708–1720.
42. 42 Denlinger, L.C., et al. Lower airway rhinovirus burden and the seasonal risk of asthma exacerbation. Am. J. Respir. Crit. Care Med. 184 (2011), 1007–1014.
43. 43 Xiang, Z., et al. Human rhinoviruses in Chinese adults with acute respiratory tract infection. J. Infect. 61 (2010), 289–298.
44. 44 Goetghebuer, T., et al. Familial susceptibility to severe respiratory infection in early life. Pediatr. Pulmonol. 38 (2004), 321–328.
45. 45 Hallstrand, T.S., et al. Airway immunopathology of asthma with exercise-induced bronchoconstriction. J. Allergy Clin. Immunol. 116 (2005), 586–593.
46. 46 Hallstrand, T.S., et al. Inflammatory basis of exercise-induced bronchoconstriction. Am. J. Respir. Crit. Care Med. 172 (2005), 679–686.
47. 47 Helenius, I.J., et al. Asthma and increased bronchial responsiveness in elite athletes: atopy and sport event as risk factors. J. Allergy Clin. Immunol. 101 (1998), 646–652.
48. 48 Helenius, I.J., et al. Respiratory symptoms, bronchial responsiveness, and cellular characteristics of induced sputum in elite swimmers. Allergy 53 (1998), 346–352.
49. 49 Fitzpatrick, A.M., et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J. Allergy Clin. Immunol. 127 (2011), 382–389.
50. 50 Karjalainen, E.M., et al. Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine. Am. J. Respir. Crit. Care Med. 161 (2000), 2086–2091.
51. 51 Farzan, S., The asthma phenotype in the obese: distinct or otherwise?. J. Allergy, 2013, 2013, 602908.
52. 52 Handschin, C., et al. The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 454 (2008), 463–469.
53. 53 Dandona, P., et al. Increase in the mediators of asthma in obesity and obesity with type 2 diabetes: reduction with weight loss. Obesity 22 (2014), 356–362.
54. 54 Dixon, A.E., et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J. Allergy Clin. Immunol. 128 (2011), 508–515.
55. 55 Hunninghake, G.W., et al. Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. Am. Rev. Respir. Dis. 128 (1983), 833–838.
56. 56 Baines, K.J., et al. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J. Allergy Clin. Immunol. 127 (2011), 153–160.
57. 57 Moore, W.C., et al. Update in asthma 2009. Am. J. Respir. Crit. Care Med. 181 (2010), 1181–1187.
58. 58 Greulich, T., et al. Detection of obstructive sleep apnoea by an electronic nose. Eur. Respir. J. 42 (2013), 145–155.
59. 59 Turner-Warwick, M., On observing patterns of airflow obstruction in chronic asthma. Br. J. Dis. Chest 71 (1977), 73–86.
60. 60 Warrell, D.A., (eds.) The Oxford Textbook of Medicine, 2015, Oxford University Press.
61. 61 Thornton, J., et al. Clinical characteristics of women with menstrual-linked asthma. Respir. Med. 106 (2012), 1236–1243.
62. 62 Foster, P.S., et al. Effect of hypothermia on beta 1-adrenoceptor-mediated relaxation of pig bronchus. Br. J. Pharmacol. 80 (1983), 699–702.
63. 63 Foster, P.S., et al. Effect of steroids on beta-adrenoceptor-mediated relaxation of pig bronchus. Br. J. Pharmacol. 78 (1983), 441–445.
64. 64 Polosa, R., et al. Managing patients with chronic severe asthma: rise to the challenge. Eur. J. Intern. Med. 20 (2009), 114–124.
65. 65 Kim, T.B., et al. Identification of asthma clusters in two independent Korean adult asthma cohorts. Eur. Respir. J. 41 (2013), 1308–1314.
66. 66 Lotvall, J., et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 127 (2011), 355–360.
67. 67 Corren, J., et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365 (2011), 1088–1098.
68. 68 Dragonieri, S., et al. An electronic nose in the discrimination of patients with asthma and controls. J. Allergy Clin. Immunol. 120 (2007), 856–862.
69. 69 Fens, N., et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am. J. Respir. Crit. Care Med. 180 (2009), 1076–1082.
70. 70 Wenzel, S., et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370 (2007), 1422–1431.
71. 71 Gauvreau, G.M., et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am. J. Respir. Crit. Care Med. 183 (2011), 1007–1014.
72. 72 Moore, W.C., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med. 181 (2010), 315–323.
73. 73 Phelan, P.D., et al. The Melbourne Asthma Study: 1964–1999. J. Allergy Clin. Immunol. 109 (2002), 189–194.
74. 74 Erpenbeck, V.J., et al. Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. J. Allergy Clin. Immunol. 111 (2003), 1319–1327.
75. 75 Bryce, P.J., Revolution 9: the backwards and forwards evidence surrounding interleukin-9. Am. J. Respir. Crit. Care Med. 183 (2011), 834–835.
76. 76 Steenwinckel, V., et al. IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J. Immunol. 178 (2007), 3244–3251.
77. 77 Kearley, J., et al. IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am. J. Respir. Crit. Care Med. 183 (2011), 865–875.
78. 78 Finnerty, J.P., et al. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am. Rev. Respir. Dis. 145 (1992), 746–749.
79. 79 Reiss, T.F., et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 52 (1997), 1030–1035.
80. 80 Bisgaard, H., et al. Long-term studies of the natural history of asthma in childhood. J. Allergy Clin. Immunol. 126 (2010), 187–197.
81. 81 Martin, P.E., et al. Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: a prospective cohort study over 4 decades. J. Allergy Clin. Immunol. 127 (2011), 1473–1479.
82. 82 Cosmi, L., et al. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J. Allergy Clin. Immunol. 125 (2010), 222–230.
83. 83 Doe, C., et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 138 (2010), 1140–1147.
84. 84 Holguin, F., et al. Obesity and asthma: an association modified by age of asthma onset. J. Allergy Clin. Immunol. 127 (2011), 1486–1493.
85. 85 Wenzel, S., Phenotypes and endotypes: emerging concepts on asthma heterogeneity. Akdis, C.A., Agache, I., (eds.) Global Atlas of Asthma., 2015, European Academy of Allergy and Clinical Immunlogy, 34–35.
86. 86 Di, D.M., et al. Xolair in asthma therapy: an overview. Inflamm. Allergy Drug Targets. 10 (2011), 2–12.
87. 87 Beck, L.A., et al. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J. Allergy Clin. Immunol. 114 (2004), 527–530.
88. 88 Korn, S., et al. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann. Allergy Asthma Immunol. 105 (2010), 313–319.
89. 89 Schumann, C., et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin. Respir. J. 6 (2012), 215–227.
90. 90 Arm, J.P., et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin. Exp. Allergy 44 (2014), 1371–1385.
91. 91 Gevaert, P., et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J. Allergy Clin. Immunol. 131 (2013), 110–116.
92. 92 Stokes, J.R., et al. The use of anti-IgE therapy beyond allergic asthma. J. Allergy Clin. Immunol. Pract. 3 (2015), 162–166.
93. 93 Hanania, N.A., et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am. J. Respir. Crit. Care Med. 187 (2013), 804–811.
94. 94 Berair, R., et al. Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma. Curr. Allergy Asthma Rep. 13 (2013), 469–476.
95. 95 Leckie, M.J., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000), 2144–2148.
96. 96 Ortega, H.G., et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371 (2014), 1198–1207.
97. 97 Castro, M., et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir. Med. 2 (2014), 879–890.
98. 98 Garcia, G., et al. Anti-interleukin-5 therapy in severe asthma. Eur. Respir. Rev. 22 (2013), 251–257.
99. 99 Castro, M., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3 (2015), 355–366.
100. 100 Holgate, S.T., Stratified approaches to the treatment of asthma. Br. J. Clin. Pharmacol. 76 (2013), 277–291.
101. 101 Holgate, S.T., Trials and tribulations in identifying new biologic treatments for asthma. Trends Immunol. 33 (2012), 238–246.
102. 102 Woodruff, P.G., et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 15858–15863.
103. 103 Choy, D.F., et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci. Transl. Med., 7, 2015, 301ra129.
104. 104 Watson, B., et al. Thymic stromal lymphopoietin: a central regulator of allergic asthma. Expert. Opin. Ther. Targets 18 (2014), 771–785.
105. 105 Gauvreau, G.M., et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N. Engl. J. Med. 370 (2014), 2102–2110.
106. 106 Fajt, M.L., et al. Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J. Allergy Clin. Immunol. 131 (2013), 1504–1512.
107. 107 Pettipher, R., et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy 69 (2014), 1223–1232.
108. 108 Diamant, Z., et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin. Exp. Allergy 44 (2014), 1044–1052.
109. 109 Yagi, R., et al. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. Int. Immunol. 23 (2011), 415–420.
110. 110 Mjosberg, J., et al. Transcriptional control of innate lymphoid cells. Eur. J. Immunol. 42 (2012), 1916–1923.
111. 111 Sel, S., et al. Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J. Allergy Clin. Immunol. 121 (2008), 910–916.
112. 112 Dicke, T., et al. Absence of unspecific innate immune cell activation by GATA-3-specific DNAzymes. Nucleic Acid Ther. 22 (2012), 117–126.
113. 113 Fuhst, R., et al. Toxicity profile of the GATA-3-specific DNAzyme hgd40 after inhalation exposure. Pulm. Pharmacol. Ther. 26 (2013), 281–289.
114. 114 Turowska, A., et al. Biodistribution of the GATA-3-specific DNAzyme hgd40 after inhalative exposure in mice, rats and dogs. Toxicol. Appl. Pharmacol. 272 (2013), 365–372.
115. 115 Homburg, U., et al. Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with T2-driven asthma. J. Allergy Clin. Immunol. 136 (2015), 797–800.
116. 116 Krug, N., et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N. Engl. J. Med. 372 (2015), 1987–1995.
117. 117 Miyanohara, T., et al. Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts. Laryngoscope 110 (2000), 126–131.
118. 118 Inamura, K., et al. The effects of erythromycin on human peripheral neutrophil apoptosis. Rhinology 38 (2000), 124–129.
119. 119 Wozniak, D.J., et al. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 125 (2004), 62–69S.
120. 120 Ianaro, A., et al. Anti-inflammatory activity of macrolide antibiotics. J. Pharmacol. Exp. Ther. 292 (2000), 156–163.
121. 121 Brusselle, G.G., et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 68 (2013), 322–329.
122. 122 Fitch, K.D., beta2-Agonists at the Olympic Games. Clin. Rev. Allergy Immunol. 31 (2006), 259–268.
123. 123 Anderson, S.D., et al. Responses to bronchial challenge submitted for approval to use inhaled beta2-agonists before an event at the 2002 Winter Olympics. J. Allergy Clin. Immunol. 111 (2003), 45–50.
124. 124 Anderson, S.D., et al. Bronchial challenges in athletes applying to inhale a beta2-agonist at the 2004 Summer Olympics. J. Allergy Clin. Immunol. 117 (2006), 767–773.
125. 125 Dickinson, J.W., et al. Impact of changes in the IOC-MC asthma criteria: a British perspective. Thorax 60 (2005), 629–632.
126. 126 Voy, R.O., The U.S. Olympic Committee experience with exercise-induced bronchospasm, 1984. Med. Sci. Sports Exerc. 18 (1986), 328–330.